TAK1 in Vascular Signaling: "Friend or Foe"?
DOI: https://doi.org/10.2147/jir.s458948
IF: 4.5
2024-05-16
Journal of Inflammation Research
Abstract:Gang Fan, 1, &ast Jingfen Lu, 2, &ast Jinhui Zha, 3, &ast Weiming Guo, 1 Yifei Zhang, 4 Yuxin Liu, 5 Liyuan Zhang 1 1 Department of Urology, Huazhong University of Science and Technology Union Shenzhen Hospital, Shenzhen, 518052, People's Republic of China; 2 The First Clinical Medical College of Guangzhou University of Chinese Medicine, Guangzhou, 510006, People's Republic of China; 3 Shenzhen University, Shenzhen, 518000, People's Republic of China; 4 The First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin, 300193, People's Republic of China; 5 College of Traditional Chinese Medicine, Hunan University of Chinese Medicine, Changsha, 410208, People's Republic of China &astThese authors contributed equally to this work Correspondence: Liyuan Zhang; Gang Fan, Department of Urology, Huazhong University of Science and Technology Union Shenzhen Hospital, Shenzhen, 518000, People's Republic of China, Email ; The maintenance of normal vascular function and homeostasis is largely dependent on the signaling mechanisms that occur within and between cells of the vasculature. TGF-β-activated kinase 1 (TAK1), a multifaceted signaling molecule, has been shown to play critical roles in various tissue types. Although the precise function of TAK1 in the vasculature remains largely unknown, emerging evidence suggests its potential involvement in both physiological and pathological processes. A comprehensive search strategy was employed to identify relevant studies, PubMed, Web of Science, and other relevant databases were systematically searched using keywords related to TAK1, TABs and MAP3K7.In this review, we discussed the role of TAK1 in vascular signaling, with a focus on its function, activation, and related signaling pathways. Specifically, we highlight the TA1-TABs complex is a key factor, regulating vascular smooth muscle cells (VSMCs) and endothelial cells (ECs) involved in the processes of inflammation, vascular proliferation and angiogenesis. This mini review aims to elucidate the evidence supporting TAK1 signaling in the vasculature, in order to better comprehend its beneficial and potential harmful effects upon TAK1 activation in vascular tissue. Keywords: TGF-β-activated kinase 1, vascular disease, mitogen-activated protein kinase, transforming growth factor-β, smooth muscle cell, endothelial cell TGF-β-activated kinase 1 (TAK1) is a protein kinase that exerts fundamental control over numerous cellular processes including inflammation, cell differentiation, and survival. 1,2 Recently, emerging evidence has affirmed the critical role of TAK1 in cardiovascular disease, a leading cause of worldwide mortality, comprising an assemblage of heart and blood vessel-related ailments encompassing coronary artery disease, stroke, and heart failure. 3,4 The pathophysiological mechanisms underpinning cardiovascular disease are multifaceted and involve a gamut of genetic and environmental determinants interconnecting with cellular signaling pathways. In the cardiovascular apparatus, TAK1 has demonstrated significant participation in the modulation of vascular function of vascular homeostasis, constriction, angiogenesis and so on, as well as targeted participation in regulating both cell death and inflammation. 5 TAK1 is a crucial signaling molecule that activates nuclear factor-kappa B (NF-κB) and mitogen-activated protein kinase (MAPK) pathways in response to various signals, such as cytokines and chemokines, and regulates inflammasomes. 6 Through TAK1, these diverse conditions and signals influence cell functions, including cell cycle, cell differentiation, immune responses, cell migration, and redox homeostasis. The dysregulation of these pathways is frequently linked to pathological vascular disease. 7,8 This review assembles evidence indicating a comparable dual role of TAK1 in cells of the vasculature and identifies potential avenues of inquiry. The objective is to advance our understanding of TAK1 signaling in cardiovascular health and disease. Transforming growth factor-β (TGF-β) is a multifaceted cytokine with the ability to regulate diverse intracellular signaling pathways. Conventionally, it is known to promote the Smad-dependent signaling pathway. 9 However, apart from the canonical Smad-dependent pathways, TGF-β1 can directly activate non-canonical, Smad-independent pathways to regulate an expansive range of downstream cellular responses. 10 TGF-β1 can activate TAK1, a serine/threonine kinase and a member of the mitogen-activated protein kinase kinase kinase (MAP3K) family, also named as MAP3K7. In addition to TGF-β1, TAK1 can be -Abstract Truncated-
immunology